Myolimus
Alternative Names: Myolimus-eluting stentLatest Information Update: 02 Oct 2021
Price :
$50 *
At a glance
- Originator Novartis
- Developer Elixir Medical Corporation
- Class Cardiovascular therapies; Lactones; Macrolides
- Mechanism of Action Immunosuppressants; MTOR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Coronary artery restenosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Coronary-artery-restenosis(Prevention) in Belgium (Intra-arterial)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Coronary-artery-restenosis(Prevention) in New Zealand (Intra-arterial)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Coronary-artery-restenosis(Prevention) in USA (Intra-arterial)